Related Experiment Video
Updated: Sep 26, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
[A long-lasting idiopathic factor V inhibitor]
Yasushi Okoshi1, Hideki Akiyama, Takashi Inoue
1Hematology Division, Tokyo Metropolitan Komagome Hospital.
Abstract:
A rare case of a long-standing idiopathic acquired blood coagulation factor V (FV) inhibitor is reported. A 78 year-old male was admitted complaining of hematuria and tarry stools of two weeks' duration. He was noted to have a prolonged prothrombin time and activated partial thromboplastin time. A mixing study suggested the existence of an inhibitor and the activity of FV was less than 1%. Western blot analysis revealed the presence of anti-FV antibodies in the patient's serum. Because of significant bleeding tendencies, the patient received fresh-frozen plasma, platelet transfusions and methylprednisolone. His PT, APTT and FV activity were partially corrected although the disease was exacerbated when the steroid dose was tapered off. The patient was then treated with low dose cyclophosphamide. The majority of the cases with acquired FV inhibitor occur spontaneously in older patients but this condition may be associated with a surgical procedure, administration of antibiotics, tuberculosis or malignant diseases; some of them are, however, idiopathic. No underlying disease was detected in our present patient. The inhibitor disappears within 10 weeks in most patients and the prolonged presence of an idiopathic FV inhibitor is rare.
Insights
This case report details a rare, long-standing idiopathic acquired blood coagulation factor V inhibitor. Treatment with immunosuppressants showed partial success, highlighting the challenges in managing this uncommon bleeding disorder.
Area of Science:
- Hematology
- Immunology
Background:
- Acquired factor V inhibitors are rare autoimmune disorders causing significant bleeding.
- Idiopathic acquired factor V inhibitors, without an underlying cause, are even rarer.
Observation:
- A 78-year-old male presented with hematuria and melena due to a factor V inhibitor with FV activity <1%.
- Mixing studies confirmed an inhibitor, and Western blot identified anti-FV antibodies.
Findings:
- Initial treatment with fresh-frozen plasma, platelets, and methylprednisolone provided partial correction of coagulation parameters.
- Disease exacerbation upon steroid dose tapering necessitated cyclophosphamide treatment.
Implications:
- This case highlights the diagnostic and therapeutic challenges of prolonged idiopathic acquired factor V inhibitors.
- The rarity and potential for relapse underscore the need for tailored, long-term management strategies.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
